Pharmaceuticals & Biotech

Are we really demonstrating value or just providing lip service?

Oct. 21, 2020 | Video | 3-minute watch

Are we really demonstrating value or just providing lip service?




In this video, ZS principal Ed Schoonveld responds to highly critical payer feedback on pharma evidence dossiers. He addresses questions such as:

  • Are pharma companies carefully considering the impact of more robust evidence options or racing to the market with a drug that customers don’t want?
  • Are companies considering all access journey customer decisions and their evidence needs that ultimately impact how many patients will have access to the drug?
  • Are companies truly considering the value needs of their customers?

Watch the video to learn ways pharma companies can strengthen evidence in trade-off with speed to launch and investment needs.

About the author(s)